Navigation Links
Milestone Scientific Reports Strong Sales Growth in First Quarter 2009 Results
Date:5/8/2009

Sales of STA Systems Increase More Than Six-Fold and Recurring Handpiece Sales Increase 22% on Comparable Quarter-Over-Quarter Basis

LIVINGSTON, N.J., May 8 /PRNewswire-FirstCall/ -- Milestone Scientific Inc. (OTC Bulletin Board: MLSS), the recognized leader in advanced injection technologies, today announced its first quarter financial results for the three months ended March 31, 2009.

Financial Highlights When Comparing Three Months Ended March 31, 2009 with Three Months Ended March 31, 2008:

  • Total revenues climbed 58% to $2.21 million, up from $1.40 million.
    • Total instrument sales rose 261% to $792,000 from $219,000.
      • Sales of the STA Single Tooth Anesthesia System(TM) totaled $617,000, up 626% over $85,000.
    • Sales of disposable handpieces increased 22% to $1.40 million from $1.15 million.
    • Overall domestic sales grew 65% to $1.48 million from $898,000.
    • International sales increased 48% to $726,000 from $490,000.
  • Total operating expenses rose 18% to $1.80 million from $1.52 million.
    • Selling, general and administrative expenses increased 17% to $1.73 million from $1.47 million, due largely to $426,000 in increased sales and marketing costs in the first quarter of this year relating to media placement, trade show participation, sales promotions, increased field sales personnel, higher third party sales commissions and international selling participation; this increase was offset by a $92,000 decrease in professional accounting services due to completion of the Sarbanes-Oxley initiative and lower audit fees and a $57,000 decrease in consulting services.
    • Research and development expenses totaled, $68,000 rising 42% from $48,000.
    '/>"/>

SOURCE Milestone Scientific Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
2. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
3. Milestone Scientific Names Robert Presutti New Vice President of Sales and Marketing
4. Milestone Scientific to Exhibit the STA(TM) System at the American Dental Associations 148th Annual Session in San Francisco
5. Smurfit-Stones Hodge, LA, Mill Becomes First to Achieve Safety Milestone
6. Grand Opening of Regence Boys & Girls Club Marks a Milestone in Historic New Columbia Community Revitalization
7. Milestone Scientific to Present at the Edgewater Research Investor Conference
8. Isis Receives $1.25 Million Milestone Payment From iCo for Initiation of Phase 1 Study of iCo-007
9. Global Gene Map Clears New Milestone
10. Free Site Offering Patient-Physician Dialog Reaches Milestone
11. Marlo Thomas and St. Jude Childrens Research Hospital(R) Announce Hitting The 50-Partner Milestone as They Kick Off the Fourth Annual Thanks and Giving(R) Campaign Which Asks America to Support St. Jude While Shopping This Holiday Season
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3Sysmex Supports Illinois Chapter Leukemia and Lymphoma Society 52505 1Sysmex Supports Illinois Chapter Leukemia and Lymphoma Society 52505 2President Obamas Health Care Plan 3A Too Big Too Expensive Too Rushed 52500 1President Obamas Health Care Plan 3A Too Big Too Expensive Too Rushed 52500 2President Obamas Health Care Plan 3A Too Big Too Expensive Too Rushed 52500 3St Johns Hospital Acquires Latest Technology in Robotic Assisted Surgery 13163 1St Johns Hospital Acquires Latest Technology in Robotic Assisted Surgery 13163 2